NCT05945823 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05945823
Title	Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Taiho Oncology, Inc.
Indications	esophagus squamous cell carcinoma gastroesophageal junction adenocarcinoma esophagus adenocarcinoma
Therapies	Cisplatin + Fluorouracil + Futibatinib + Pembrolizumab Fluorouracil + Futibatinib + Leucovorin + Oxaliplatin + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| FRA \| ESP \| DEU

NCT05945823
Clinical Trial Detail